Dear E,

The COVID-19 pandemic has caused significant disruptions to clinical development, and we send our best wishes and heartfelt support to all those whose lives and work have been affected by this outbreak. While this is a difficult time for so many, we in the drug development industry—particularly those in the infectious disease and vaccine space—have the opportunity to turn the tide on this pandemic and bring relief to those who are suffering.  

Helping sponsors get their cures approved and in the hands of those most in need is a true passion of ours, and getting it done in the context of a global pandemic is something we've done already. During the 2009 H1N1 pandemic, the NIH turned to Rho to rapidly develop and coordinate a national, multisite research project to evaluate the immunogenicity and dosing of the H1N1 vaccine in those with asthma. In less than 18 months, the study team went from the initial study idea to publication of the primary study results in the Journal of Allergy and Clinical Immunology.

Our clinical development and submissions experts also bring industry-leading experience with NIH, DHHS, and the Biomedical Advanced Research and Development Authority (BARDA). We are 1 of 5 CROs in the BARDA Medical Counter Measures Clinical Studies Network, which includes the development of drugs, vaccines, and diagnostics that ensure public safety against the threats of bioterrorism, pandemics, and other emerging diseases. Recent awarded studies include Panblok H7 Influenza Vaccine and Anthrax Vaccine in populations older than 65. 

We are excited about the opportunity to help find a cure for COVID-19, and we would love to schedule a meeting with you to discuss how we can bring our expertise and drive to your infectious disease or vaccine program.

Best,

Lisa Payne